Reference is made to the stock exchange announcement published by Nykode
Therapeutics ASA (the "Company") on 24 October 2023 regarding the successful
placing of a private placement of new shares (the "Private Placement"). 

Datum Opportunity AS, a company controlled by Jan Haudemann-Andersen, will as a
result of lending shares in connection with settlement of the Private Placement
temporarily reduce its shareholding in the Company from 26,000,000 shares, equal
to 8.80% of the current registered share capital of the Company, to 0 shares,
thereby crossing the 5% disclosure threshold. The aggregate shareholdings of Jan
Haudemann-Andersen and companies controlled by him (including Datum Opportunity
AS) will temporarily be reduced from 40,689,050 shares, equal to 13.77% of the
current registered share capital of the Company, to 11,139,650 shares, equal to
3.77% of the current registered share capital of the Company, thereby crossing
the 10% and 5% disclosure thresholds.

Upon re-delivery of borrowed shares following registration of the share capital
increase pertaining to the Private Placement, Datum Opportunity AS will hold an
unchanged total of 26,000,000 shares, equal to 8.00% of the expected new share
capital of the Company, and Jan Haudemann-Andersen and companies controlled by
him (including Datum Opportunity AS) will hold an unchanged aggregate of
40,689,050 shares, equal to 12.52% of the expected new share capital of the
Company.

This announcement is made in accordance with Section 4-2 of the Norwegian
Securities Trading Act.